Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine.
about
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patientsMRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and PitfallsACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.Liver iron content determination by magnetic resonance imaging.Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseasesMagnetic resonance imaging measurement of iron overload.Cardiovascular magnetic resonance T2* for tissue iron assessment in the heart.Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition.Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.New developments and controversies in iron metabolism and iron chelation therapy.Management of the thalassemiasLongitudinal analysis of heart and liver iron in thalassemia major.Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonancePancreatic iron loading predicts cardiac iron loading in thalassemia major.Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.Use of magnetic resonance imaging to monitor iron overloadGlutathione S-transferase gene polymorphism: Relation to cardiac iron overload in Egyptian patients with Beta Thalassemia Major.Myocardial and liver iron overload, assessed using T2* magnetic resonance imaging with an excel spreadsheet for post processing in Tunisian thalassemia major patients.Iron deposits in the knee joints of a thalassemic patient.Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deMRI-based evaluation of multiorgan iron overload is a predictor of adverse outcomes in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.Quantitative T2* magnetic resonance imaging for evaluation of iron deposition in the brain of β-thalassemia patients.ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents
P2860
Q26826936-56972E02-4222-4CB7-B447-556A1AAE2855Q28072173-54CD37DB-1867-4FA0-A28D-77A324B07243Q30475186-4DAC8C6C-C57E-41B1-9A5C-1A24FB12F2C7Q33670385-28C6FAB8-A288-4AC7-B926-E21F14470212Q33764777-770DE889-3812-40F2-A641-898A884A38A2Q33909024-60041A63-893D-441D-9E58-A6A32B3686D7Q33909042-48FA5DF8-ADEA-4B89-8CC4-2BCAC09ACEBAQ33944366-0DA9A743-5D96-4670-8F13-81CC959ECCA1Q34422736-CCBDE872-45F5-49BB-96BF-169DD4DF2751Q34786236-26B7E3B6-4F76-457F-A0FF-544ACB9A774CQ36532618-FA607EE5-60FB-4807-BB92-EE56810AE7F9Q36719376-C5906DC1-8BF9-4AF2-88C4-60C2FBDD0C3DQ36870253-F734A02A-E1CD-4DC2-8DCB-A2F261C9A06EQ36915941-649A331F-E3A0-440D-9F83-EB104AA51335Q36926651-C7F9AAB1-1902-48F9-AEF0-67BF14B798A3Q37414689-95663D91-3D6C-48BF-B124-1518D82D6D1EQ37528626-E380DA9E-6E07-41B9-8B33-45F079693CD2Q38099045-FB5B6F95-310A-4690-B171-B07D5D3B45FFQ38234248-CE26032F-F7D9-4C1B-BBED-C5AE8D4B6FBBQ39260470-9881CFE5-6E41-49CE-A10B-BC77292312DCQ39300721-0CAAFCD4-F6C8-41AF-A95D-38F234C35708Q41827664-13ECFC9C-0087-4E7F-833E-14D033CE77C8Q42783336-ABF40A99-4358-4D33-8BF8-68F84D25941DQ43265088-482B0265-7E9A-4F72-9A16-DBEF75F6328FQ47138026-153F2184-3F3F-454A-92D7-F07AA4BC67B2Q48787004-840C5990-BC11-4299-9FE7-129746690C3FQ57736172-F50CD0A6-F4BF-4DE0-A400-95652AC2DFB9
P2860
Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Development of thalassaemic ir ...... compliance to desferrioxamine.
@en
Development of thalassaemic ir ...... compliance to desferrioxamine.
@nl
type
label
Development of thalassaemic ir ...... compliance to desferrioxamine.
@en
Development of thalassaemic ir ...... compliance to desferrioxamine.
@nl
prefLabel
Development of thalassaemic ir ...... compliance to desferrioxamine.
@en
Development of thalassaemic ir ...... compliance to desferrioxamine.
@nl
P2093
P2860
P356
P1433
P1476
Development of thalassaemic ir ...... compliance to desferrioxamine
@en
P2093
Beatrix Wonke
Emma Prescott
Lisa J Anderson
Mark A Westwood
P2860
P304
P356
10.1159/000089475
P577
2006-01-01T00:00:00Z